Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program


Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds

Cambridge, UK, 06 August 2012: Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, today announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKε oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a number of lead compounds against a panel of X-MAN™ isogenic disease model human cell lines, which accurately model the mutations found in cancer cells.

Profiling of Domainex’s lead TBK1/IKKε dual inhibitor molecules against the X-MAN cell lines will enable identification of the effect of individual mutations on drug activity and resistance and prediction of which patient sub-groups will respond.  This will help guide the medicinal chemistry optimization program and will provide important patient stratification data for future partnering.

“Horizon’s oncology and genome editing expertise are a valuable complement to our in-house biochemistry, medicinal chemistry and computer aided drug design capabilities,” commented Eddy Littler, CEO of Domainex. “We look forward to working together to efficiently and cost-effectively develop a drug molecule for this important target. We also look forward to future collaborations with Horizon on Domainex’s epigenetic pipeline in oncology and with the wide number of projects that Domainex supports on behalf of its clients”

Kam Dhaliwal, Director of Business Development, Horizon said: “We are delighted that Domainex has chosen to collaborate with Horizon on their lead program, and look forward to leveraging our   Discovery Toolbox and Oncology expertise to help guide the program.”

Horizon’s Discovery Toolbox is based on its proprietary precision rAAV-mediated genome editing technology (GENESIS™), over 450 X-MAN human isogenic cell lines that more accurately model patient genetics (known as “patients in a test tube”), and 2D and 3D phenotypic assays. The Toolbox enables the recapitulation of the patient situation in vitro and allows screening of the most important activated cancer genes and pathways found in patients, under conditions that mimic the micro environment of the disease.

Financial terms of the agreement are not disclosed.

 ENDS

Notes to Editors

Contacts:

At Horizon:

Kam Dhaliwal

Director of Business Development

Tel: +44 (0)1223 655 580

Email: Reveal email address

Media enquiries for Horizon:

Katie Odgaard

Zyme Communications

Tel: +44 (0)7787 502 947

Email email

At Domainex:

Joanne McCudden

Head of Business Development

Email: Reveal email address

Comments are closed.